News

The equity stake is part of an agreement under which Shire granted three central nervous system (CNS) pre-clinical development programs to Chronos in return for milestones and an

Fast Track designation is granted by FDA to drugs that are under development for serious conditions and have the potential to fulfill an unmet medical need. It was

The 280,000ft² facility will serve as a major hub for the North American life science business of Merck. It will feature a customer collaboration laboratory and training center

With the new indication, patients with moderate to severe Alzheimer's disease, who are currently stabilized on Aricept, donepezil hydrochloride (10 mg), can now start combination therapy directly with

The purpose of the new company Neostell is to produce Neovacs' Kinoid immunotherapy product candidates including IFNα-Kinoid, in clinical development for the treatment of systemic lupus erythematosus (lupus).

“The alarming rise of Zika, and the sharp increase in neurological disorders seen in affected areas, intensifies the need to develop a safe and effective vaccine capable of

Vernalis and Servier have been working in partnership using Vernalis' proprietary fragment and structure-based drug discovery platform on a number of oncology targets, including Bcl-2 and Mcl-1. This

Qtern is a fixed-dose combination of saxagliptin and dapagliflozin, two oral blood glucose lowering medicines, indicated in adults aged 18 years and older with type 2 diabetes. It intends to

The reference product is approved in the European Union for use in moderate to severe rheumatoid arthritis (RA), ankylosing spondylitis, moderate to severe plaque psoriasis, active and progressive